Browse drugs

…enralizumab, dupilumab, mepolizumab, omalizumab, reslizumab and tezepelumab, were estimated using Medicine Carbon Footprint Classifier, a s…

…numab 300 mg biweekly; and -44.15% (95% CI -50.44 to -37.86) vs baricitinib 2 mg diary. Statistically significant differences were found be…

…12 (10–60) 4.5 (0–80) 7.5 (0–10) 0 (0–10) 8.5 (3–10) 3.5 (0–10) Baricitinib 22 (21–40) 1 (0–18) 16 (5–40) 1 (0–10) 6 (0–1) 0 (0–1) 8 (0–5) …

…s but developed serious side effects. In her current pregnancy, dupilumab was introduced at week 30 (off-label use), leading to significa…

… microscopy was employed to validate molecular findings.Results REGN668 inhibits patient-specific processes in malignant lymphocytes; h…

…025 GOLD guidelines, which formally integrate biologics such as dupilumab and mepolizumab for patients with elevations in peripheral eosi…

…rate was 89%, and 37.8% used the telepharmacy chat for queries. Dupilumab was the most frequent biologic (45.2%). Pulmonary function impr…

…sturbances and activity limitations. Biologic therapies such as omalizumab and dupilumab are established options for antihistamine-refract…

…arthritis was the most frequent diagnosis (30%).Drugs involved: adalimumab (35%), etanercept (25%), certolizumab (8%), belimumab (6%), ixe…

…the only without polysorbate). Consequently, desensitisation to tezepelumab was proposed.Results The content of the commercial pen (CP) (21…

… 41.9% allergy and atopic dermatitis. Biologics prescribed were omalizumab (61.4%), dupilumab (22.7%), mepolizumab (11.4%), and tezepeluma…

…and nasal polyposis 29.2% (12/41). Biologic therapies used were dupilumab 48.7% (20/41), benralizumab 24.4% (10/41), tezepelumab 12.2% (5…